Frequently searched
↑ ↓ to move · Enter to open · Esc to closeSynonyms and typos are matched
Trial site
Active, not recruiting
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
NCT04708041· Phase 3· Merck Sharp & Dohme LLC· Source
Site data: ClinicalTrials.govUpdated 12 Nov 2026
Report an error